Its use is limited by many side effects, including renal tubular acidosis (RTA), mainly of the distal type. In this study, rats were treated with FK506 and at baseline (after 9 days) systemic acid-base status was similar to that in control animals. However, FK506-treated rats given NH 4Cl in the drinking water for 2 days developed a more severe metabolic acidosis than control animals. Urine pH was more alkaline, but net acid excretion was normal. After 7 days of acid load, all differences related to acid-base homeostasis were equalized in both groups. Protein abundance of type IIa Na-P i cotransporter, type 3 Na ϩ /H ϩ exchanger, and electrogenic Na ϩ -bicarbonate cotransporter, and both a4 and B2 subunits of the vacuolar H ϩ -ATPase were reduced under baseline conditions, while induction of metabolic acidosis enhanced protein abundance of these transporters in FK506-treated animals. In parallel, protein expression of AE1 was reduced at baseline and increased together with pendrin during NH 4Cl loading in FK506 rats. Protein abundance of the Na ϩ -bicarbonate cotransporter NBCn1 was reduced under baseline conditions but remained downregulated during metabolic acidosis. Morphological analysis revealed an increase in the relative number of non-type A intercalated cells in the connecting tubule and cortical collecting duct at the expense of principal cells. Additionally, subcellular distribution of the a4 subunit of the vacuolar H ϩ -ATPase was affected by FK506 with less luminal localization in the connecting tubule and outer medullary collecting duct. These data suggest that FK506 impacts on several major acid-base transport proteins in the kidney, and its use is associated with transient metabolic acidosis and altered expression of key renal acid-base transport proteins. anion exchanger; pendrin; H ϩ -ATPase; collecting duct CALCINEURIN INHIBITORS LIKE FK506 (tacrolimus) are potent immunosuppressive drugs that are routinely used following solid organ transplantation in conjunction with other antiproliferative agents. The use of tacrolimus is often limited by many side effects such as tremor, hemolytic-uremic syndrome, arterial hypertension, hyperlipidemia, and a higher incidence of new-onset diabetes mellitus. Despite these adverse side effects, FK506 can also be nephrotoxic, causing reduced glomerular filtration rate (GFR) and distal renal tubular acidosis (dRTA), which are strongly restrictive for continuing the drug (21, 37, 39) . Several studies in renal organ transplant patients have observed a significant correlation between dRTA and tacrolimus treatment (22, 27, 44) . In addition, the prevalence of RTA in renal transplant recipients with a functioning graft has been associated with treatment with calcineurin inhibitors such as FK506 (22, 44). It appears that among the various calcineurin inhibitors, FK506 is more prone than cyclosporine to cause dRTA (22, 44) .
anion exchanger; pendrin; H ϩ -ATPase; collecting duct CALCINEURIN INHIBITORS LIKE FK506 (tacrolimus) are potent immunosuppressive drugs that are routinely used following solid organ transplantation in conjunction with other antiproliferative agents. The use of tacrolimus is often limited by many side effects such as tremor, hemolytic-uremic syndrome, arterial hypertension, hyperlipidemia, and a higher incidence of new-onset diabetes mellitus. Despite these adverse side effects, FK506 can also be nephrotoxic, causing reduced glomerular filtration rate (GFR) and distal renal tubular acidosis (dRTA), which are strongly restrictive for continuing the drug (21, 37, 39) . Several studies in renal organ transplant patients have observed a significant correlation between dRTA and tacrolimus treatment (22, 27, 44) . In addition, the prevalence of RTA in renal transplant recipients with a functioning graft has been associated with treatment with calcineurin inhibitors such as FK506 (22, 44) . It appears that among the various calcineurin inhibitors, FK506 is more prone than cyclosporine to cause dRTA (22, 44) .
Despite the high prevalence of various forms of posttransplant RTA, little is known about the direct effects of calcineurin inhibitors such as FK506 on the regulation of renal acid-base balance and the underlying molecular mechanisms.
Measurements of the maximum acidification capability of renal allograft recipients showed a slight decrease in H ϩ secretion during FK506 treatment, suggesting a direct impact of FK506 on renal tubular function (22) . Additional studies have provided insight into the pathophysiological role of cyclosporine in RTA. Watanabe et al. (54) have shown that cyclosporine A produces dRTA by blocking the peptidyl prolyl cis-trans isomerase (PPIase) activity of cyclophilin in rats and thus preventing the adaptive inhibition of bicarbonate-secretoryintercalated cells after acute acid incubation (3 h). Moreover, calcineurin homologous protein (CHP), a widely expressed protein with significant similarity to the regulatory B subunit of calcineurin, has been purported to influence the function and expression of the Na ϩ /H ϩ exchanger NHE3 by activation of the adenosine receptor A 1 R (15) . Finally, studies in calcineurin A␤ Ϫ/Ϫ mice showed a marked decrease in type IIa Na ϩ -phosphate cotransporter mRNA levels and a lack of compensatory increase following treatment with a low-phosphate diet, indicative of a direct effect of calcineurin on a renal-specific transport protein (35) . Hence, it is likely that calcineurin may also be involved in the regulation of other transport proteins involved in renal acid-base handling.
The aim of the present study was to investigate the molecular mechanisms of (distal) RTA induced by FK506 treatment. We used a rat model treated either with FK506 or saline solution (control) and examined acid-base status, renal acid excretion, and expression of key acid-base transport proteins under basal conditions and during an acute and chronic acid loading with NH 4 Cl.
Despite lower expression of several acid-base transporters, acid-base status was normal in FK506-treated rats. Interestingly, FK506-treated animals developed a more severe metabolic acidosis when presented with an acid challenge like NH 4 Cl.
MATERIALS AND METHODS

Animal Model
Male Wistar rats (Janvier Elevage, Le Genest-St.-Isle, France), weighing 150 -200 g, were equally divided into six groups: 1) saline (control), 2) FK506 injections, 3) saline plus 2 days of NH 4Cl treatment, 4) FK506 injections plus 2 days of NH 4Cl treatment, 5) saline plus 7 days of NH4Cl treatment, and 6) FK506 injections plus 7 days of NH4Cl treatment. Daily subcutaneous injections of FK506 (1 mg/kg body wt) were given for either 9 days (groups 2ϩ4) or 14 days (group 6), respectively, whereas control animals received daily injections of physiological saline (0.9% NaCl) only. FK506 was kindly provided by Astellas Pharma (Munich, Germany) and dissolved in 0.9% NaCl according to the manufacturer's protocol. All animals were given free access to drinking water supplemented with 1% sucrose and maintained on a standard diet as previously reported by us and others (8, 12, 18, 34, 42) . Animals were placed in individual metabolic cages for the final 4 days of the experimental treatment. Animals treated with NH 4Cl received 0.28 M NH4Cl in 1% sucrose in the drinking water to induce metabolic acidosis (3, 5, 11, 29, 40) . Body weights were documented daily, and urine was collected under mineral oil. All animal experiments were performed according to national and international guidelines and laws of animal welfare and protocols approved by the local Veterinary Authority (Veterinaeramt Zurich).
Blood and Urine Analysis
At the end of experiments, rats were anesthetized by intraperitoneal injections of ketamine and xylazine, and heparinized arterial blood was collected from the tail artery and analyzed immediately for pH, blood gases, and electrolytes on a Radiometer ABL 800 Flex bloodgas analyzer (Radiometer, Copenhagen, Denmark). Ion chromatography (Metrohm ion chromatograph, Herisau, Switzerland) was performed to determine urinary K ϩ , Na ϩ , Cl Ϫ , Ca 2ϩ , and Mg 2ϩ concentrations. Serum creatinine, phosphate, and glucose concentrations were measured using the clinical chemistry analyzer Piccolo Xpress (LabForce, Nunningen, Switzerland). Urine pH, PCO 2, and calculated HCO3 were determined by aspirating urine from the collectors into gas-tight syringes and injecting it immediately into the blood-gas analyzer. Urinary creatinine was analyzed using the Jaffé method (45, 46) . Urinary ammonium concentration was determined using the Berthelot protocol (6). Determination of titratable acids was performed as previously described (13) . Briefly, a mixture of equal volumes of urine and 0.1 N HCl was boiled for 2 min. After the mixture was cooled for 10 min, titration with 0.1 N NaOH to pH 7.40 at 37°C was performed. A blank sample (distilled water) was treated in an identical way. The difference in volumes of NaOH required to titrate the sample and the blank, multiplied by the normality of NaOH ϫ 1,000, revealed the concentration of titratable acids (in mmol/l). Osmolarity of blood and urine was determined using a Roebling osmometer (Auer Bittmann Sourié, Dietikon, Switzerland) by examination of freezing-point depression. Glomerular filtration rates, fractional excretion of ions, anion gap, and net acid excretion were calculated from the measured values. To test for lowmolecular-weight proteinuria, urine samples were normalized by creatinine. Samples containing 10 mg creatinine were then solubilized in Laemmli sample buffer, and SDS-PAGE was performed on a 15% polyacrylamide gel. Colloidal Coomassie blue staining was performed for 1 h at room temperature. After destaining for ϳ2 h, the gel was photographed and dried. Five micrograms of BSA served as a positive control.
Immunoblotting
Rats were anesthetized with ketamine/xylazine and perfused through the left ventricle with warm (37°C) sucrose/phosphate buffer (140 mM sucrose, 28 mM NaH 2PO4, 112 mM Na2HPO4, pH 7.4), and the kidneys were removed rapidly and frozen under liquid nitrogen and placed at Ϫ80°C until further analysis. Frozen kidneys were then used for crude membrane and brush border membrane (BBM) preparation as described previously using the Mg 2ϩ precipitation technique (7) . After measurement of the protein concentration (Bio-Rad Dc Protein Assay, Bio-Rad, Hercules, CA), 50 g of crude membrane protein or 20 g of BBM protein was solubilized in Laemmli sample buffer, and SDS-PAGE was performed on 8 -12% polyacrylamide gels. Proteins were transferred electrophoretically from gels to polyvinylidene difluoride membranes (Immobilon-P, Millipore, Bedford, MA). After blocking with 5% milk powder in Tris-buffered saline containing 0.1% Tween 20 for 60 min, the blots were incubated with the respective primary antibodies overnight at 4°C or 2 h at room temperature [see table of primary antibodies used (Supplementary Table 1 ); all supplementary material for his article are accessible on the journal web site]. After washing and subsequent blocking, blots were incubated with the secondary antibody (donkey anti-rabbit or sheep anti-mouse antibodies linked to horseradish peroxidase 1:10,000, GE Healthcare, Little Chalfont, Buckinghamshire, UK) or goat anti-rabbit antibody 1:5,000 linked to alkaline phosphatase (Promega, Madison, WI) for 1 h at room temperature. Antibody binding was detected with the Immobilon Western chemiluminescence kit (Millipore, Billerica, MA), using the DIANA III-chemiluminescence detection system (Raytest, Straubenhardt, Germany). All images were analyzed using appropriate software (Advanced Image Data Analyzer, Raytest) to calculate the protein of interest/actin ratio.
Immunohistochemistry
Rats were anesthetized as described above and subsequently perfused through the left ventricle with PBS followed by a paraformaldehyde-lysine-periodate fixative (33) . Kidneys were removed and fixed overnight at 4°C by immersion in paraformaldehyde-lysineperiodate. Kidneys were washed three times with PBS, and after cryoprotection with PBS/30% sucrose solution for at least 12 h, thin coronal slices were cut, mounted on thin cork plates, and frozen in liquid propane cooled with liquid nitrogen. Immunostaining was carried out as described previously (49) . Briefly, 5-m thin sections were incubated with 1% SDS for 5 min, washed three times with PBS, Values are means Ϯ SE; n ϭ 8 -9/group. A summary of arterial blood and urine data from control (NaCl injected) and FK506-treated rats after 9 days of treatment is shown. TA, titratable acids; NAE, net acid excretion. *P Ͻ 0.05.
†P Ͻ 0.01. ‡P Ͻ 0.001.
and incubated with PBS containing 1% BSA for 15 min before application of the primary antibody. The primary antibodies (Supplementary Table 1 ) were diluted in PBS and applied either for 75 min at room temperature or overnight at 4°C. Sections were then washed twice for 5 min with high-NaCl-PBS (PBSϩ18 g NaCl/l), once with PBS, and incubated with dilutions of the secondary antibodies [donkey anti-rabbit Alexa 594 1:1,000, donkey anti-mouse Alexa 488 1:400, donkey anti-goat Alexa 488 1:400 (Invitrogen, Basel, Switzerland) and DAPI 1:500 (Sigma)] at the given dilutions for 1 h at room temperature. Sections were again washed twice with high-NaCl-PBS and once with PBS before being mounted with Vectashield (Vector Laboratories, Burlingame, CA). Sections were viewed using a LCSM Leica confocal microscope. Pictures were processed (overlaid) using Adobe Photoshop software. Cell counting for the different subtypes of cells along the collecting duct was performed as described previously (9, 49) .
Statistical Analysis
All data are presented as means Ϯ SE and were tested for significance using the unpaired t-test or one way ANOVA test. Results with P Ͻ 0.05 were considered statistically significant.
RESULTS
Animal Model
Baseline mean body weight and age were similar between all groups. Treatment with FK506 was associated with a significantly lower gain in body weight and with body weight loss after induction of metabolic acidosis with NH 4 Cl loading (Tables 1-3) .
Interestingly, all FK506-treated animals were found to have mild hyperglycemia and a reduced creatinine clearance, which are common side effects of FK506 (Tables 1-3) (21, 26, 51, 55) .
Under baseline conditions, blood analysis showed no difference in arterial blood gases or acid-base status between control and FK506-treated animals ( Table 1 , Fig. 1 ). Similarly, urinary parameters showed no significant changes in volume or osmolality; however, compared with control animals, FK506-treated animals excreted significantly more acidic urine, more ammonium, more phosphate, and markedly less bicarbonate, sodium, and potassium in urine ( Table 1 , Fig. 1 ).
Since rats treated with FK506 displayed no spontaneous acid-base disorder and to test for adaptive changes in renal acid excretion secondary to an acute or chronic acid challenge, rats were given 0.28 M NH 4 Cl in drinking water for 2 and 7 days, respectively. Both treatment time points induced metabolic acidosis, observed as reduced arterial blood pH paralleled by decreased arterial bicarbonate levels and a fall in arterial PCO 2 as a compensatory response (Tables 2 and 3) . FK506-treated rats demonstrated a more severe metabolic acidosis after 2 days compared with control animals (Table 2, Fig. 1 ). In addition, urinary pH of FK506-treated animals was inappropriately alkaline ( Table 2 , Fig. 1 ).
Interestingly, after 7 days of acid load both control and FK506-treated rats showed similar blood-gas status and urinary Values are means Ϯ SE; n ϭ 8 -9/group. Shown is a summary of arterial blood and urine data from control (NaCl-injected) and FK506-treated rats after 2 days of oral acid loading (0.28 M NH4Cl in drinking water). *P Ͻ 0.05. †P Ͻ 0.01. ‡P Ͻ 0.001. Values are means Ϯ SE; n ϭ 8-9/group. Shown is a summary of arterial blood and urine data from control (NaCl-injected) and FK506-treated rats after 7 days of oral acid loading (0.28 M NH4Cl in drinking water). *P Ͻ 0.05. †P Ͻ 0.01. pH and no difference in net acid excretion, revealing that both groups are able to adapt to a similar extent (Table 3) .
FK506 Alters Protein Abundance of Key Renal Acid-Base Transport Proteins
Proximal tubular proteins. Immunoblotting showed a small but significant decrease in the protein abundance of the major renal Na ϩ /H ϩ exchanger isoform 3 (NHE3) and a marked reduction in the Na ϩ -phosphate cotransporter NaPi-IIa in the BBM of FK506-treated rats compared with control animals. Similarly, the abundance of the B2 and a4 subunits of the vacuolar H ϩ -ATPase was reduced in the BBM of FK506-treated animals ( Fig. 2A, Table 4 ). In parallel with decreased abundance of apical transport proteins, expression of the basolateral electrogenic Na ϩ -bicarbonate cotransporter, kNBCe1, was also strongly reduced (Fig. 2B, Table 4) .
Distal nephron. Treatment with FK506 was associated with a significant decrease in protein abundance of the type A intercalated cell-specific Cl Ϫ /HCO 3 Ϫ exchanger kAE1 in the cortex and medulla (Fig. 2, B and C, Table 4 ). In contrast, protein abundance of the non-type A intercalated cell-specific Cl Ϫ /HCO 3 Ϫ exchanger pendrin was not significantly changed between FK506-treated and control animals (Fig. 2B, Table 4 ). Additionally, expression of the a4 (ATP6V0A4) subunit of the vacuolar H ϩ -ATPase was also decreased in cortical membrane preparations of the whole kidney, while a4 protein abundance of medullary membrane preparations was slightly increased (Fig. 2C, Table 4 ). In contrast, protein abundance of the B1 (ATP6V1B1) subunit was similar in both groups, whereas a significant decrease of the electroneutral Na ϩ -bicarbonate cotransporter NBCn1 was found. (Fig. 2C, Table 4 ) (28).
Treatment with FK506 Alters Adaptive Response of Renal Acid-Base Transport Proteins to Metabolic Acidosis
Proximal tubular proteins. In contrast to baseline conditions, immunoblotting of NaPi-IIa showed a marked increase in protein abundance after 2 days of acid load in FK506-treated rats compared with acid-loaded control animals (Fig. 3A, Table 4 ). This was consistent with a higher rate of urinary phosphate excretion after 2 days of acid load in the control group ( Table 2 ). The abundance of the apical proton-extruding proteins NHE3 and the a4 subunit of the vacuolar H ϩ -ATPase was similarly increased in the FK506 rats. In contrast, B2 H ϩ -ATPase subunit expression did not differ between both groups (Fig. 3A, Table 4 ) and kNBCe1 protein abundance was significantly lower in the FK506-treated animals compared with controls (Fig. 3B, Table 4 ). Chronic acid loading (7 days) caused similar increases in protein abundances of the proximal tubular transport proteins NaPi-IIa, NHE3, and the a4 and B2 subunits of the H ϩ -ATPase in the FK506-treated group (Fig. 4A, Table 4 ). Nevertheless, urinary phosphate excretion did not differ between FK506-treated animals and control rats after 7 days of acid load (Table 3) .
Distal nephron: kAE1 and pendrin. In contrast to baseline conditions, the abundance of both Cl Ϫ /HCO 3 Ϫ exchangers of the distal nephron, namely, kAE1 and pendrin, were increased in the FK506-treated animals after 2 days of NH 4 Cl loading (Fig. 3, B and C, Table 4 ). Protein abundance of the a4 subunit of the H ϩ -ATPase was markedly elevated in cortical and medullary membrane preparations of FK506-treated rats. However, protein abundance of the B1 subunit was not different, while NBCn1 expression was decreased in the FK506 group (Fig. 3, B and C, Table 4 ). In parallel to changes in protein levels after an acute acid load, abundance of the a4 subunit of Fig. 1 . Arterial blood pH, urinary pH, and acid excretion in control and FK506-treated animals. Shown is a summary of blood and urinary data of control (saline injected) and FK506-treated rats under baseline conditions and after 2 or 7 days of oral acid loading (0.28 M NH4Cl). A and B: treatment with FK506 induced a more severe metabolic acidosis after 2 days of acid loading, paralleled by inappropriately alkaline urine compared with control rats. However, after 7 days acid load both groups displayed metabolic acidosis but no significant differences were detected. C: under baseline conditions and after 2 days of acid load, FK506-treated rats had significantly increased urinary ammonium excretion compared with control animals. D: net acid excretion was calculated as urinary ammonium excretion plus titratable acids minus bicarbonate excretion. No significant difference between both groups was detected under all conditions; n ϭ 8 -9/group. Significant difference between control and FK506-treated rats: *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. the H ϩ -ATPase, pendrin, and AE1 was significantly increased in the FK506-treated group after 7 days of acid load (Fig. 4 , B and C, Table 4 ). There were no significant changes in protein levels of the B1 subunit after 2 and 7 days of acute acid load (Figs. 3B and 4B, Table 4 ).
Remodeling of the Distal Nephron
Immunohistochemistry was performed to test the effect of FK506 on the relative abundance of acid-secretory type A intercalated cells and bicarbonate-secretory non-type A intercalated cells. We used AE1 and pendrin as specific markers of type A intercalated cells and non-type A intercalated cells, respectively. Principal cells in the connecting tubule and collecting duct were marked with calbindin D 28k and the AQP2 water channel (31) .
Under baseline conditions, detailed analysis of the connecting tubule (CNT) and cortical collecting duct (CCD) showed a significant increase in pendrin positive (non-type A) intercalated cells in FK506-treated rats compared with control animals that was not according to the changes in protein expression detected by immunoblotting. The number of principal cells was significantly less in this group. However, after 2 days of acid load we could not detect any significant changes in the relative cell numbers of non-type A intercalated cells as well as type A intercalated and principal cells between FK506-treated animals and control rats (see Fig. 5 , Table 5 ).
Analysis of AE1-positive cells in the outer and inner stripe of the inner medullary collecting ducts revealed no significant changes in the relative cell numbers of FK506-treated rats and control animals, respectively (Fig. 6, Table 5 ). Furthermore, induction of metabolic acidosis after 2 days NH 4 Cl loading did not reveal any difference in the relative cell numbers of type A intercalated cells in these segments between control and FK506-treated animals (Fig. 6 , Table 5 ).
In addition, the subcellular distribution of staining for the a4 subunit of the vacuolar H ϩ -ATPase was analyzed to determine differences in proton pump trafficking. Detailed analysis revealed less a4 staining associated with the luminal membrane in the CNT and outer medullary collecting duct of FK506-treated rats under baseline conditions. After 2 days of acid load, no difference in subcellular localization between both groups could be detected, with the exception of less luminal a4 staining in the CNT of FK506-treated animals (Table 6) .
Taken together, treatment with FK506 is associated with a remodeling of the initial parts of the collecting system, with an increase in the relative number of bicarbonate-secretory nontype A intercalated cells and a decrease in principal cell number under baseline conditions.
DISCUSSION
RTA is one of the most common side effects of calcineurin inhibitors like FK506, and its use is restricted when side effects such as RTA are noted (21, 37, 39) . To identify the etiology underlying renal tubular acidosis secondary to FK506 treatment, we used a rat model. Measurements of creatinine clearance and blood glucose levels were pathologically changed, consistent with previously described adverse effects of FK506 use in humans as well as in rats (21, 26, 51, 55) . Additionally, treatment with FK506 resulted in lower mean body weights compared with controls, which was markedly significant when combined with NH 4 Cl treatment. Use of another calcineurin inhibitor, cyclosporine, has been previously described in rats, resulting in similar findings (19, 25) . Thus the rat model used here mimics some of the major side effects of FK506 in humans.
FK506-treated animals had increased urinary phosphate excretion paralleled by reduced protein abundance of the major Fig. 2 . Expression of key acid-base transport proteins under baseline conditions. A: immunoblotting of brush-border membrane proteins including the type IIa Na ϩ -phosphate cotransporter (NaPi-IIa), Na ϩ /H ϩ exchanger isoform 3 (NHE3), and the a4 (ATP6V0A4) and B2 (ATP6V1B2) subunits of the H ϩ -ATPase from control (saline injected) and FK506-treated rats. B: membrane fraction of total kidney cortex was analyzed for the basolateral electrogenic Na ϩ -bicarbonate transporter NBCe1, the apical Cl Ϫ /HCO 3 Ϫ exchanger pendrin, the type A intercalated cell-specific anion exchanger AE1, and the a4 and B1 subunits of the H ϩ -ATPase. C: kidney medullary membrane fraction was prepared and analyzed for the type A intercalated cell-specific anion exchanger AE1, the a4 subunit of the H ϩ -ATPase, and the electroneutral Na ϩ -bicarbonate cotransporter NBCn1. All membranes were stripped and reprobed for ␤-actin (not shown).
renal phosphate cotransporter NaPi-IIa. Similarly, treatment with the calcineurin inhibitor cyclosporine has recently been shown to result in a marked decrease in NaPi-IIa mRNA levels both in vitro in opossum kidney cells and in vivo in kidneys of rats fed a low-phosphate diet (35) . Furthermore, data from mice with genetic deletion of the calcineurin A␤ gene showed significantly decreased NaPi-IIa mRNA expression and a reduced compensatory response to a low-phosphate diet (35) . Thus calcineurin inhibitors can directly affect regulated expression of the NaPi-IIa cotransporter.
In the proximal tubule, we detected lower NHE3 abundance in the brush-border membrane. The impact of calcineurin inhibitors on NHE3 may be complex. Cyclosporine has been reported to stimulate apical NHE3 activity in proximal tubular cells which was mediated by Ca 2ϩ release from intracellular stores (17) . On the other hand, CHP interacts with NHE3 and appears to be essential for its function (38) but is also involved in the inhibitory effect of adenosine on NHE3 function (15) .
In the distal nephron, decreased protein expression of NBCn1 and kAE1 was observed in our study. Downregulation of AE1 protein abundance was not reflected in the number of AE1-expressing cells, as shown by analysis of relative cell numbers in the different segments of the collecting system. In contrast, the relative number of pendrin-expressing (non-type A) intercalated cells along the CNT and CCD was significantly increased in the FK506-treated rats. Remodeling of the collecting duct has been observed under various conditions such as chronic treatment with carbonic anhydrase inhibitors (4) or acute and chronic metabolic acidosis. Interconversion of nontype A intercalated cells to type A intercalated cells as well as proliferation of type A intercalated cells and removal of nontype A intercalated cells, respectively, have been suggested (1, 43, 51a) . The higher abundance of pendrin-positive intercalated cells suggests a disequilibrium between different intercalated cell subtypes that may impair the ability of the collecting duct to fine-tune final acid excretion, similar to what has been also reported by Watanabe et al. (54) . This effect was secondary to inhibition of the cyclophilin activity by cyclosporine since inhibition of calcineurin alone (by FK506) did not affect the adaptive response in the CCD (54) . Thus cyclophilin may be required for the rapid response within hours whereas calcineurin may modulate more chronically the expression of pendrin and subsequently the number of non-type A intercalated cells. A role of calcineurin in the collecting duct is further supported by the fact that calcineurin may be involved in AQP2 water channel regulation and trafficking (30) . However, we did not find any evidence for disturbed AQP2 expression or localization ( Supplementary Fig. 3 ).
After induction of metabolic acidosis with 2 days of NH 4 Cl load, a more pronounced and transient metabolic acidosis was observed in FK506-treated rats compared with control rats. The etiology of this more severe metabolic acidosis is not entirely clear. Respiratory compensation was normal (as indicated by the lower PCO 2 ), we did not observe diarrhea, and urinary net acid excretion was similar in both groups. However, urinary pH was inappropriately high and the anion gap was normal. A more alkaline urine has also been reported from rats treated with cyclosporine, and microperfusion experiments suggested reduced H ϩ -ATPase-mediated proton secretion (50). In our experiments, Western blotting demonstrated increased protein levels of several H ϩ -ATPase subunits in the proximal tubule and collecting duct. In yeast, calcineurin is required for assembly of functional H ϩ -ATPase subunits (23). Here we observed a significant difference in the subcellular distribution of the a4 subunit by immunohistochemistry, with less staining associated with the luminal membrane, consistent with reduced proton secretion by H ϩ -ATPases. Thus treatment with FK506 may disrupt normal assembly and function/trafficking of H ϩ -ATPases in the cells in the distal nephron. Furthermore, FK506-treated animals responded to this acid challenge with an increase in protein abundance of the kAE1 exchanger and pendrin. AE1 changes may occur as a part of a compensatory effort since similar changes have been reported in models of pure metabolic acidosis (2, 10, 24, 36, 40, 47, 52) . In contrast, increased expression of pendrin in the FK506 group is in contrast to its downregulation during acidosis.
Chronic acid load with 7 days' NH 4 Cl treatment resulted in a similar metabolic acidosis in both FK506-treated and control rats. Respiratory compensation was present in both groups, as evidenced by low PCO 2 values. Also, urinary pH, urinary ammonium excretion, and net acid excretion were similar in both groups. However, protein abundance of NaPi-IIa, NHE3, the a4 subunit of the H ϩ -ATPase, and kAE1 was increased. Also, pendrin protein expression remained markedly upregulated in the FK506 group. Values are means of the normalized relative protein abundance Ϯ SE; n ϭ 4 -5/group. BBM, brush-border membrane; NaPi-IIa, type IIa Na-Pi cotransporter; NHE3, Na ϩ /H ϩ exchanger isoform 3; kNBCe1, electrogenic Na ϩ -bicarbonate cotransporter; kAE1, anion exchanger 1; NBCn1, electroneutral Na ϩ -bicarbonate cotransporter. All blots were analyzed by calculating the ratio of the protein of interest to ␤-actin. Subsequently, the protein abundance of the FK506-treated animals was normalized to the control animals. Significant difference comparing FK506 groups to the corresponding controls: *P Ͻ 0.05; †P Ͻ 0.01; ‡P Ͻ 0.001.
Surprisingly, under baseline conditions FK506-treated animals did not demonstrate any signs of metabolic acidosis or impaired urinary acidification, suggesting compensatory mechanisms such as reduced GFR, increased urinary phosphate excretion, or more distally active transporters to compensate for these changes. However, the development of metabolic acidosis is difficult to explain only based on the changes in kidney transport proteins described here and in the face of normal net acid excretion. Thus other extrarenal factors may contribute to the development of more severe metabolic acidosis in FK506 rats during short-term NH 4 Cl loading. We did not observe diarrhea or differences in the serum anion gap and lactate levels (data not shown) which could explain acidosis. These findings are in contrast to reports from patients with kidney transplantation and FK506 treatment. However, it has to be considered that not all transplant patients develop RTA when receiving FK506, clearly indi- Fig. 3 . Expression of key acid-base transport proteins after 2 days of acid load. A: immunoblotting of the Na ϩ -phosphate cotransporter NaPi-IIa, NHE3, and the B2 and a4 H ϩ -ATPase subunits in brush-border membranes after 2 days of acid loading. B: membrane fraction of total kidney cortex was analyzed for NBCe1, the apical Cl Ϫ /HCO 3 Ϫ exchanger pendrin, the type A intercalated cell-specific anion exchanger AE1, and the a4 (ATP6V0A4) and B1 (ATP6V1B1) subunits of the H ϩ -ATPase. C: kidney medullary membrane fraction was prepared and analyzed for the type A intercalated cell-specific anion exchanger AE1 and the a4 and B1 subunits of the H ϩ -ATPase. All membranes were stripped and reprobed for ␤-actin (not shown). cating that additional factors play an important or permissive role. Hence, additional events may be necessary to prime the kidney, such as ischemia during transplantation. In fact, kidney transplantation alone is sufficient to elicit RTA in some patients.
In summary, treatment with FK506 in the rat is associated with dysregulation of major acid-base transporters in the proximal tubule and the distal nephron and may thus impair the kidney's ability to respond appropriately to an acute acid load. The chronic adaptation to acid loading is preserved or even exaggerated in Values are means Ϯ SE, with the number of cells counted in parentheses. Shown is a summary of cell counts in the different segments of the collecting system. Two kidney sections from 3-4 animals in each group were analyzed, and cells were counted. CNT, connecting tubule; CCD, cortical collecting duct; OMCD, outer medullary collecting duct; IMCDi, initial segment of the inner medullary collecting duct; d, days. Significant difference between control and FK506-treated animals: *P Ͻ 0.01, †P Ͻ 0.001. Fig. 5 . FK506 affects non-type A intercalated cell abundance in the cortical collecting duct (CCD). Kidneys were stained with antibodies against pendrin (red) and calbindin D28k/ aquaporin-2 (AQP2; combined and shown in green) as markers of non-type A intercalated cells and principal cells, respectively. A and B: staining for pendrin in the CCD of control and FK506-treated rats under baseline conditions. Non-type A intercalated cells (stained in red with pendrin) are indicated by an asterisk and type A intercalated cells (not stained for pendrin or calbindin D28k/AQP2) by arrowheads. C: segment-specific analysis of relative cell numbers demonstrated a significant increase in pendrin-positive cells in the CCD under baseline conditions. In parallel, the relative number of pendrin-negative and calbindin D28k/AQP2-positive cells was decreased significantly in FK506-treated rats. D: after 2 days of acid load, there was no significant difference in the relative cell number of all different cell types between control rats and FK506-treated animals. Significant difference between control and FK506-treated rats, ***P Ͻ 0.001; original magnification ϫ400.
kidneys from FK506-treated rats. To our knowledge, this is the first study describing these changes in compensatory mechanisms in the collecting system during treatment with the calcineurin inhibitor FK506, but more studies are needed to fully elucidate the molecular mechanisms involved. Values are means Ϯ SE, with the number of cells counted in parentheses. Shown are summarized data from counts of the predominant subcellular distribution of the a4 subunit of the vacuolar H ϩ -ATPase in the intercalated cells in the distal nephron in control and FK506-treated rats in the absence or presence of an acute acid load with NH4Cl for 2 days. Two kidney sections from 3-4 animals in each group were analyzed, and cells were counted. Significant difference between control and FK506-treated animals, *P Ͻ 0.05. Fig. 6 . FK506 has no effect on the relative number of type A intercalated cells in the outer medullary collecting duct (OMCD). Kidneys were stained with antibodies against AE1 (red) and calbindin D28k/AQP2 (combined and shown in green) as markers of type A intercalated cells and principal cells, respectively. A and B: staining for AE1 in the OMCD of control and FK506-treated rats under baseline conditions. Type A intercalated cells (stained in red with AE1) are indicated by an asterisk and non-type A intercalated cells (not stained for AE1 or calbindin D28k/AQP2) by arrowheads. C and D: segment-specific analysis of relative cell numbers demonstrated no significant differences for all cell types in the OMCD under baseline conditions (C) and after acid loading for 2 days (D). Original magnification ϫ400.
GRANTS
